吉西他滨联合伊立替康在紫杉类/铂类方案失败的NSCLC中的应用探讨  

A Study of Bi-Weekly Gemcitabine and Irinotecan as Second-Line Chemotherapy in Non-Small Cell Lung Cancer After Prior Taxane+Platinum-Based Regimens

作　　者：王雪涛[1] 

机构地区：[1]聊城市人民医院肿瘤科,山东聊城252000

出　　处：《肿瘤基础与临床》2008年第4期346-347,共2页journal of basic and clinical oncology

摘　　要：目的对GEM＋CPT-11方案在治疗复发NSCLC中可行性及有效性进行评价。方法PS评分≤2，先期以紫杉类／铂类为基础化疗的进展期NSCLC20例。给药方案：GEM1500mg／m^2。＋CPT-11150mg／m^2，d1,15，每28d为1周期。结果20例可进行评价。部分缓解3例（15％），稳定8例（40％），进展9例（45％）。Ⅲ-Ⅳ度粒细胞减少4例（20％），发热性粒细胞减少1例（5％）。无Ⅲ度以上血小板减少。Ⅲ度腹泻1例（5％），Ⅱ度腹泻3例（15％）。结论对于先期紫杉类＋铂类化疗失败的进展期NSCLC，GEM＋CPT-11方案是有效的，且患者耐受性良好。Objective To evaluate the feasibility and efficacy of bi-weekly gemcitabine （GEM） ＋ irinotecan （CPT-11） in patients with relapsed NSCLC. Methods Patients with advanced NSCLC, whose performance status （PS） ≤2, prior taxane/platinum-based chemotherapy was eligible. Results 20 patients were evaluable for a response and toxicity. Objective responses were PR, 3/20 （ 15% ） ; stable disease, 8/20 （40%） ; and progressive disease, 9/20 （45%）. Grade Ⅲ-Ⅳ neutropenia was seen in 4 patients（20% ） and febrile neutropenia in 1 patient（5% ）. No Grade Ⅲ-Ⅳ thrombocytopenia was seen, grade Ⅲ diarrhea in 1 patient（5% ） and grade Ⅱ in 3 patients（ 15% ）. Conclusion Bi-weekly GEM ＋ CPT-11 is active and well tolerated in patients with advanced NSCLC failing prior taxane ＋ platinum regimens.

关 键 词：吉西他滨 伊立替康 化疗 非小细胞肺癌 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]